Co-Diagnostics Q3 2023 Earnings Report $0.49 +0.01 (+2.50%) As of 03:57 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Earnings HistoryForecast Co-Diagnostics EPS ResultsActual EPS-$0.20Consensus EPS -$0.29Beat/MissBeat by +$0.09One Year Ago EPSN/ACo-Diagnostics Revenue ResultsActual Revenue$2.46 millionExpected Revenue$0.20 millionBeat/MissBeat by +$2.26 millionYoY Revenue GrowthN/ACo-Diagnostics Announcement DetailsQuarterQ3 2023Date11/9/2023TimeN/AConference Call ResourcesPress ReleaseCODX Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Powered by Co-Diagnostics Earnings HeadlinesCo-Diagnostics, Inc. and CoSara to Host HPV and Cancer Symposium on International HPV Day 2025March 3 at 9:30 AM | prnewswire.comCo-Diagnostics (NASDAQ:CODX) vs. Globus Medical (NYSE:GMED) Financial SurveyFebruary 28, 2025 | americanbankingnews.com“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 different coins that have returned over 100%... But today, Chris is now making the biggest crypto call of his ENTIRE career…March 4, 2025 | True Market Insiders (Ad)Penny Stock Co-Diagnostics Withdraws FDA Application For COVID-19 Test, Plans To Submit Enhanced VersionFebruary 24, 2025 | benzinga.comCVRx (NASDAQ:CVRX) versus Co-Diagnostics (NASDAQ:CODX) Financial SurveyFebruary 24, 2025 | americanbankingnews.comCo-Diagnostics Withdraws FDA Application for Covid TestFebruary 21, 2025 | marketwatch.comSee More Co-Diagnostics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Co-Diagnostics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Co-Diagnostics and other key companies, straight to your email. Email Address About Co-DiagnosticsCo-Diagnostics (NASDAQ:CODX), a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.View Co-Diagnostics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Analysts Lift Archer Aviation Stock Despite Earnings Miss DigitalOcean Rides Cloud Wave and AI Hype to Strong EarningsPrice Targets on NVIDIA Rise in Front of EarningsThe Trade Desk Crashes on Earnings, But Growth Catalysts PersistHims & Hers Earnings Could Be a Game Changer—What to Do NowAnalysts See Buying Opportunity in NVIDIA Before EarningsAirbnb's Earnings: Sky High Results, Grounded Guidance? Upcoming Earnings Marvell Technology (3/5/2025)Broadcom (3/6/2025)Costco Wholesale (3/6/2025)JD.com (3/6/2025)Canadian Natural Resources (3/6/2025)Oracle (3/10/2025)Adobe (3/12/2025)PDD (3/19/2025)Micron Technology (3/20/2025)Accenture (3/20/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
